Baird analyst Joe Vruwink initiates coverage on ResMed (NYSE:RMD) with a Outperform rating and announces Price Target of $280.
Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.